Kristina Lindemann, Head of the Gynecological Oncology Center at Oslo University Hospital, shared on LinkedIn:
“Today, we had the opportunity to welcome members of the Norwegian Parliament, Erlend Larsen (Høyre) and Ragnhild Bergheim (Ap), to Oslo University Hospital and Oslo Cancer Cluster Incubator for an important discussion about the future of clinical trials in Norway.
It was a pleasure to share insights into our work in gynaecological cancer clinical trials in close Nordic and European collaboration.
Clinical trials are essential to improving cancer care. They provide patients with access to innovative treatments, generate the evidence needed to change clinical practice, and strengthen the connection between research and patient care.
But clinical trials are about much more than healthcare alone.
They are also closely linked to research policy, innovation, international competitiveness and Norway’s position in European and global cancer research.
If we want the Nordic countries to remain an attractive country for international clinical trials, we need long-term investment, strong research infrastructure and political commitment.
Many thanks to Erlend Larsen and Ragnhild Bergheim for their interest and engagement, and to colleagues at Oslo Cancer Cluster, the Unit for European Cancer Cooperation, Oslo University Hospital, for bringing us together for this valuable exchange.”
You can also read: Kristina Lindemann: Oslo University Hospital Expands Opportunities for Industry-Sponsored Oncology Trials.